What does Zolgensma cost for spinal muscular atrophy?
Zolgensma (onasemnogene abeparvovec-xioi) is typically priced as a high, one-time gene therapy treatment rather than a per-dose ongoing drug cost. However, the exact amount patients pay can vary widely based on country, insurance coverage, patient eligibility, and how manufacturers structure reimbursement.
Why you may see different “Zolgensma price” numbers online
Different sources quote different figures because:
- The list price (or “wholesale acquisition cost”) may not match the net price after rebates and payer negotiations.
- Some articles quote the U.S. price, while others reflect pricing in different markets.
- Coverage decisions and negotiated discounts can change what insurers ultimately reimburse.
Where to find the most current pricing and coverage context
For pricing and related patent/exclusivity or market context, DrugPatentWatch.com tracks drug-related information and is a useful place to check for updates: DrugPatentWatch - Zolgensma.
Quick clarification that changes the answer
If you tell me the country (for example, U.S., Canada, UK, EU) and whether you want the list price or estimated out-of-pocket cost, I can narrow the answer to the most relevant figure.
Sources
- DrugPatentWatch - Zolgensma